Fibromyalgia research: where the science is heading

4–7 minutes

Key takeaways

Fibromyalgia is increasingly framed as a disorder of central pain processing, with research now investigating biological mechanisms.

The strongest recent lead is an immune one, from a 2021 study in mice that has not yet been confirmed in humans.

Other active areas include small fibre neuropathy, the gut microbiome, and the search for diagnostic biomarkers.

A cure is not close, but after decades of treating only the symptoms, research has started to investigate the underlying cause.

For decades, fibromyalgia was dismissed as a psychological condition or stress response. The lack of a visible marker on standard blood tests meant many clinicians treated it as unexplained, and research funding was limited.

That has started to change, though more slowly than the scale of the illness warrants. Fibromyalgia affects around 2% of the UK population. It is diagnosed far more often in women, though estimates of the ratio vary widely and depend on which criteria are used.


Is fibromyalgia an autoimmune disease?

One of the most significant developments came in 2021. A team from King’s College London, the University of Liverpool, and Sweden’s Karolinska Institute published a study in the Journal of Clinical Investigation.

They injected mice with antibodies from people with fibromyalgia. The mice developed fibromyalgia-like symptoms: increased pain sensitivity, reduced movement, and changes to the small nerve fibres in the skin. Mice injected with antibodies from people without the condition showed no such effects.

The finding suggested that fibromyalgia may be driven, at least in part, by the immune system rather than originating in the brain. If confirmed, it opens a new category of potential treatments. Some are already used for other autoimmune conditions, such as therapies that reduce antibody levels.

The hypothesis is a major development, but it has not yet been independently replicated at scale. Not all researchers agree it explains the full symptom picture. Some question how antibodies could produce symptoms such as sensitivity to light or smell, which are clearly neurological.

This is active research: one of the most hopeful directions in the field, but not yet a settled account of what fibromyalgia is.

In 2023, the Sir Jules Thorn Charitable Trust awarded £1.7 million to Dr David Andersson at King’s College London. The grant funds work on possible diagnostic tests and therapeutic approaches.


Other active research areas

Research into fibromyalgia is not focused on any single mechanism. Several distinct threads are making progress.

Small fibre neuropathy
A substantial proportion of people with fibromyalgia show changes to the small nerve fibres in the skin. These findings support the idea that fibromyalgia has a measurable physical basis. Researchers are still working out the relationship between small fibre damage and symptoms.

Central sensitisation
Research continues into how the central nervous system processes pain signals in fibromyalgia, and why ordinary sensory input can register as painful.

The gut microbiome
Studies consistently find differences in the gut bacteria of people with fibromyalgia. Research teams, notably a group led by Dr Amir Minerbi in Israel and Canada, have linked specific microbiome patterns to fibromyalgia symptoms. It is not yet clear whether these differences cause the condition, reflect it, or both.

Biomarker research
Several teams are searching for reliable blood-based markers to support diagnosis. A 2025 Spanish study using proteomic analysis identified candidate protein markers that differed between people with fibromyalgia and healthy controls. Biomarker work is still early, but it is the foundation of the diagnostic tests the condition currently lacks.

These are active research areas, not settled conclusions. Findings are promising but early.


Funding and the wider picture

Fibromyalgia research remains significantly underfunded relative to the number of people affected. In the United States, the American Fibromyalgia Syndrome Association has published critical analyses of National Institutes of Health spending. It argues that a meaningful portion of ostensibly fibromyalgia-related funding goes to other conditions, or to exercise and behavioural studies of limited clinical value.

In the UK, there is no dedicated public funding stream for fibromyalgia research comparable to the commitments being made for ME/CFS and long COVID. Progress here has depended largely on individual research teams securing competitive grants, and on charities such as Versus Arthritis funding specific projects.

The picture is not uniformly discouraging. The 2023 Sir Jules Thorn award is substantial. Research into long COVID is beginning to produce findings with possible relevance to fibromyalgia, given the overlap in post-viral symptom patterns. The volume of fibromyalgia research published internationally has also risen steadily over the past decade.

But the field is not yet where it needs to be. There is no dedicated national strategy. No genetic study on the scale of ME/CFS’s DecodeME. And no single funder treating fibromyalgia as a priority condition in its own right rather than a variant of something else.


Is a treatment coming?

A single treatment that cures fibromyalgia is not coming soon, but the picture is no longer hopeless.

In August 2025, the US FDA approved Tonmya, a sublingual form of cyclobenzaprine, and the first drug approved specifically for fibromyalgia in around fifteen years. It treats symptoms rather than the underlying mechanism, mainly the disturbed sleep that feeds pain and fatigue. It is not approved in the UK.

Its significance here is that fibromyalgia is back on the drug-development map.

The most promising longer-term possibility is that antibody-reducing therapies, already used for other autoimmune conditions, may be trialled in fibromyalgia. If the autoimmune hypothesis continues to hold up, that could change management meaningfully for some people.

But clinical trials take years, and even then the benefit may not extend to everyone. Not every person with fibromyalgia necessarily shares the same underlying mechanism.

The realistic near-term goal is not a cure. It is better diagnostic tools, and a clearer understanding of who responds to which existing treatment. Eventually, it may mean a small number of targeted therapies for specific subtypes.

For people living with fibromyalgia today, that does not change the immediate situation. But for the first time, the field is investigating mechanisms rather than only managing symptoms.


Related pages

Fibromyalgia symptoms
Pain, fatigue, sleep, fibro fog, and sensory sensitivity, in plain language.

Fibromyalgia news
How to spot reliable updates and follow real scientific progress.

Fibromyalgia and overlapping conditions
The high rate of co-occurrence with ME/CFS, IBS, migraine, and other conditions.

Managing fibromyalgia
Pain management, sleep, gentle movement, and working with your GP.

Fibromyalgia resources
Patient charities, research organisations, tracking tools, and communities.